Recent Investment Analysts’ Ratings Updates for Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (NASDAQ: RARE) has recently received a number of price target changes and ratings updates:

• 11/5/2026 – Ultragenyx Pharmaceutical had its price target lowered by Citigroup from $32.00 to $22.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Ultragenyx Pharmaceutical had its price target lowered by Barclays from $35.00 to $32.00. They now have an “overweight” rating on the stock.
• 11/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by Canaccord Genuity Group from $39.00 to $34.00. They now have a “buy” rating on the stock.
• 11/4/2026 – Ultragenyx Pharmaceutical had its price target raised by TD Cowen from $18.00 to $19.00. They now have a “buy” rating on the stock.
• 11/4/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $20.00 to $22.00. They now have an “equal weight” rating on the stock.
• 11/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by The Goldman Sachs Group from $19.00 to $17.00. They now have a “neutral” rating on the stock.
• 11/4/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $18.00 to $19.00. They now have an “equal weight” rating on the stock.
• 11/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by Wedbush from $25.00 to $22.00. They now have a “neutral” rating on the stock.
• 10/15/2026 – Ultragenyx Pharmaceutical is now covered by UBS Group. They set a “neutral” rating and a $16.00 price target on the stock.
• 10/14/2026 – Ultragenyx Pharmaceutical was upgraded by UBS Group to “hold”.
• 10/6/2026 – Ultragenyx Pharmaceutical had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/23/2026 – Ultragenyx Pharmaceutical was upgraded by William Blair to “hold”.
• 9/21/2026 – Ultragenyx Pharmaceutical had its price target raised by Barclays from $32.00 to $35.00. They now have an “overweight” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Citigroup from $31.00 to $32.00. They now have a “buy” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Canaccord Genuity Group from $37.00 to $39.00. They now have a “buy” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Cantor Fitzgerald from $33.00 to $39.00. They now have an “overweight” rating on the stock.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE traded down $0.86 during trading hours on Tuesday, hitting $15.55. 480,763 shares of the company were exchanged, compared to its average volume of 2,878,417. The company has a market capitalization of $1.53 billion, a PE ratio of -3.00 and a beta of 0.37. The firm has a fifty day simple moving average of $15.84 and a 200-day simple moving average of $22.68. Ultragenyx Pharmaceutical Inc. has a one year low of $12.73 and a one year high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million during the quarter, compared to the consensus estimate of $182.49 million. During the same quarter in the previous year, the business earned ($1.81) earnings per share. The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -3.21 EPS for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the sale, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 8,510 shares of company stock worth $127,561 over the last ninety days. 5.20% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders.

Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.